Company profile
Nutranomics, Inc.
OTC: NNRX · Healthcare · Drug Manufacturers - Specialty & Generic
#818 of 1,422 Healthcare companies by revenue26th-percentile growth
EA Score
——FH —DQ 10GM —SS 30
v0.1 · 25/100 weight · pillars only
↑ listing tenure, Altman-Z · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$3.1M
Rev growth YoY (TTM)
+46.4%
Net income (FY)
-$1.2M
Employees
1
as of 2026-08-26
Market cap
$816.2k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.8M$1.8M2015
Net income-$1.2M-$1.2M2015
Operating income-$836.1k-$836.1k2015
Total assets$448.7k$448.7k2015
Liabilities$1.9M$1.9M2015
Equity-$1.5M-$1.5M2015
Revenue trend
FY2014 – FY2015 · USD
FY14
FY14
FY15
Revenue by segment
Filed disclosures · FY2014
By product
Product Sales100%
Nutritional Blood Analysis Services0%
By geography
Americas66%
South Asia Pacific21%
CHINA11%
North Asia1%
Europe0%
Middle East0%
The read
What is Nutranomics, Inc.’s revenue?
Nutranomics, Inc. booked $1.8M in FY2015 revenue, contracting 26% year over year — slower than 74% of Healthcare companies we track, at a -68.0% net margin.
Peers · Healthcare
Innovative MedTech Inc.49DBeleave Inc.——Bionik Laboratories Corp.——CanaFarma Hemp Products Corp.——Spectral Medical Inc31DVolitionRX Ltd40DNeighbors
Salt Lake →Key facts
CEOJonathan Bishop
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSalt Lake City, UT
ExchangeOTC: NNRX
Employees1
IPO date2013-04-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.